METHOD TO PREDICT THE RESPONSE TO CANCER TREATMENT WITH ANTI-PD1 IMMUNOTHERAPY

Cancer is one of the most studied diseases in recent years, due to its high incidence and mortality. The use of immune control inhibitors, ICBs, has revolutionized cancer treatment, as acceptable toxicity and long-lasting response have been demonstrated in responders. The use of the programmed death ligand inhibitor (anti-PD1) is a common treatment in patients with advanced melanomas, which has been shown to have a 20% higher response rate than with chemotherapy and with better tolerability. However, a percentage of patients are insensitive or develop resistance, so it is necessary to have a pattern of predictive biomarkers that allows deciding whether or not to use anti-PD1. In this invention, a molecular biomarker profile is identified, which allows patients to be classified according to their response profile, based on gene expression variations.